Fax: (011) 39 0116635267
p63 expression as a new prognostic marker in Merkel cell carcinoma
Article first published online: 28 JUN 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 3, pages 640–647, 1 August 2007
How to Cite
Asioli, S., Righi, A., Volante, M., Eusebi, V. and Bussolati, G. (2007), p63 expression as a new prognostic marker in Merkel cell carcinoma. Cancer, 110: 640–647. doi: 10.1002/cncr.22828
- Issue published online: 18 JUL 2007
- Article first published online: 28 JUN 2007
- Manuscript Accepted: 17 APR 2007
- Manuscript Revised: 30 MAR 2007
- Manuscript Received: 22 DEC 2006
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- Piedmont Region
- Compagnia di San Paolo “Special Project Oncology”
- Fondazione Internazionale di Ricerca in Medicina Sperimentale (FIRMS), Turin, Italy
- Merkel cell carcinoma;
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor, mostly affecting elderly individuals. The histogenesis of this rare tumor as well as its prognostic criteria are a matter of dispute.
An immunohistochemical analysis of markers of proliferation (Ki-67/MIB-1), neuroendocrine differentiation (chromogranin A and synaptophysin), and basal cell differentiation (p63) was performed in a series of 47 cases of MCC. The significance of pathologic data and of immunoreactivity with different markers was evaluated using the chi-square test. Survival curves were calculated using the Kaplan-Meyer method. The survival difference was estimated using the Wilcoxon or Mantel-Cox test.
Immunohistochemical evidence of neuroendocrine differentiation and immunopositivity for cytokeratin 20 were observed in all cases, whereas positivity for p63 was detected in approximately half of the cases (25 of 47 cases; 53.2%). Cases that were positive for p63 demonstrated a more aggressive clinical course than those that were negative (Z value of 2.93; P = .0003; hazards ratio of 22.22).
Data from the current study indicate that p63 expression is associated with a worse prognosis in patients with MCC and represents a new independent marker of clinical evolution. Cancer 2007. © 2007 American Cancer Society.